Skip to main content

Melanoma risk doubled in childhood cancer survivors

Compared with the general population, childhood cancer survivors have a twofold increased risk for melanoma, with substantially worse survival for those who develop invasive melanoma.

Read more

Editor's Choice

Asciminib discontinuation feasible in CML

There are minimal data concerning treatment-free remission after discontinuation of the novel TKI asciminib in people with chronic myeloid leukemia. These two cases provide proof of principle that sustained TFR is possible in selected patients.

Spondyloarthritis and cancer risk

The risk for malignancy in people with spondyloarthritis remains a controversial issue. What is the current evidence for the impact of the disease and its treatment with biologic and targeted synthetic DMARDs?

Coffee and tea drinkers may have reduced risk for HNC

A pooled analysis has revealed an inverse association between coffee and tea consumption and the risk for developing head and neck cancer.

Current and future immunotherapy for breast cancer

Explore the recent major clinical trials of immunotherapy in breast cancer and find out more about promising emerging options, such as vaccines, bispecific antibodies, and cellular therapies.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now

Case Studies

Asciminib discontinuation feasible in CML

There are minimal data concerning treatment-free remission after discontinuation of the novel TKI asciminib in people with chronic myeloid leukemia. These two cases provide proof of principle that sustained TFR is possible in selected patients.

Primary vitreoretinal lymphoma mimics fungal endophthalmitis

PVRL is a life-threatening neoplasm. It can be mistaken for non-infectious uveitis, as it often presents with vitritis that responds to corticosteroids, but this case shows that it can also mimic infectious uveitis.

Late-onset ICI-related pneumonitis

Pneumonitis related to ICI therapy typically occurs within the first few months of treatment, but this lung cancer patient experienced the adverse event 2.5 months after discontinuing pembrolizumab, underscoring the need for long-term vigilance.

At a glance: The KEYNOTE lung cancer trials

A quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in non-small-cell and small-cell lung cancer.

Developed by: Springer Medicine
Read more

Current Reviews

Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine

Adrenal diseases pose significant diagnostic challenges due to the wide range of neoplastic and non-neoplastic pathologies. Radiologists have a crucial role in diagnosing and managing these conditions by, leveraging advanced imaging techniques.

AI image analysis as the basis for risk-stratified screening

Artificial intelligence (AI) has emerged as a transformative tool in breast cancer screening, with two distinct applications: computer-aided cancer detection (CAD) and risk prediction. While AI CAD systems are slowly finding its way into clinical …

PET radiomics for histologic subtype classification of non-small cell lung cancer: a systematic review and meta-analysis

Lung cancer is the leading cause of cancer morbidity and mortality among adults [ 1 , 2 ]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases [ 3 ]. Globally, it is estimated that there are more than 2.48 …

TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds

Globally, breast and ovarian cancers are major health concerns in women and account for significantly high cancer-related mortality rates. Dysregulations and mutations in genes like TP53, BRCA1/2, KRAS and PTEN increase susceptibility towards …

Episode 9: The gut microbiome and CAR T-cell therapy

How do nutrition, supplements and antibiotics impact patient outcomes?

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

Prof. Marion Subklewe
Listen now

CME & eLearning

SPONSORED

Webinar

1.5 European CME credits (ECMEC®s)

A series of patient cases underpin this interactive webinar that aims to provide practical guidance on a multidisciplinary approach to managing patients with cutaneous T-cell lymphoma.

Sponsored by:
  • Kyowa Kirin
Developed by: Springer Healthcare

Symposium (Link opens in a new window)

An independent symposium at the 10th COMy World Congress focusing on BCMA-targeting strategies for the treatment of multiple myeloma. Gain insights into the latest clinical data and the implications for clinical practice.

Supported by:
  • GlaxoSmithKline
Developed by: Springer Healthcare IME

eLearning (Link opens in a new window)

The evolving landscape of metastatic urothelial carcinoma brings with it many challenges, such as optimally sequencing therapies and managing adverse events. Navigate your way through these with the Ultimate mUC challenge game and expert-to-expert interviews.

Supported by:
  • Merck Healthcare KGaA, Darmstadt, Germany and Astellas
Developed by: Springer Healthcare IME

Further Reading

Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience

As median age of patients with acute myeloid leukemia is 72 years, older patients continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well as leukemia-specific unfavorable …

Ethnic enclaves, neighborhood socioeconomic status, and obesity among Hispanic women in Chicago: a latent profile analysis approach

  • Open Access
  • Obesity
  • Original Paper

The Hispanic population in the United States (U.S.) constitute of close to 65 million individuals. They are the largest, second-fastest-growing, and the second most segregated minority group in the U.S., following Asians, [ 1 , 2 ]. The prevalence …

Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine

Adrenal diseases pose significant diagnostic challenges due to the wide range of neoplastic and non-neoplastic pathologies. Radiologists have a crucial role in diagnosing and managing these conditions by, leveraging advanced imaging techniques.

AI image analysis as the basis for risk-stratified screening

Artificial intelligence (AI) has emerged as a transformative tool in breast cancer screening, with two distinct applications: computer-aided cancer detection (CAD) and risk prediction. While AI CAD systems are slowly finding its way into clinical …

Related topics

Asciminib discontinuation feasible in CML

There are minimal data concerning treatment-free remission after discontinuation of the novel TKI asciminib in people with chronic myeloid leukemia. These two cases provide proof of principle that sustained TFR is possible in selected patients.

Read more

Melanoma risk doubled in childhood cancer survivors

Compared with the general population, childhood cancer survivors have a twofold increased risk for melanoma, with substantially worse survival for those who develop invasive melanoma.

Read more